These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29651283)

  • 1. miRNAs in Tuberculosis: New Avenues for Diagnosis and Host-Directed Therapy.
    Sabir N; Hussain T; Shah SZA; Peramo A; Zhao D; Zhou X
    Front Microbiol; 2018; 9():602. PubMed ID: 29651283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNAs in immune responses to Mycobacterium tuberculosis infection.
    Yang T; Ge B
    Cancer Lett; 2018 Sep; 431():22-30. PubMed ID: 29803788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA research: The new dawn of Tuberculosis.
    Mehta P
    Indian J Tuberc; 2021 Jul; 68(3):321-329. PubMed ID: 34099196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers.
    Sinigaglia A; Peta E; Riccetti S; Venkateswaran S; Manganelli R; Barzon L
    Cells; 2020 Sep; 9(10):. PubMed ID: 32987746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of microRNAs and Long Non-Coding RNAs in the Regulation of the Immune Response to
    Kundu M; Basu J
    Front Immunol; 2021; 12():687962. PubMed ID: 34248974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monocyte and Macrophage miRNA: Potent Biomarker and Target for Host-Directed Therapy for Tuberculosis.
    Sampath P; Periyasamy KM; Ranganathan UD; Bethunaickan R
    Front Immunol; 2021; 12():667206. PubMed ID: 34248945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs as immune regulators and biomarkers in tuberculosis.
    Wang L; Xiong Y; Fu B; Guo D; Zaky MY; Lin X; Wu H
    Front Immunol; 2022; 13():1027472. PubMed ID: 36389769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprogramming of Small Noncoding RNA Populations in Peripheral Blood Reveals Host Biomarkers for Latent and Active Mycobacterium tuberculosis Infection.
    de Araujo LS; Ribeiro-Alves M; Leal-Calvo T; Leung J; Durán V; Samir M; Talbot S; Tallam A; Mello FCQ; Geffers R; Saad MHF; Pessler F
    mBio; 2019 Dec; 10(6):. PubMed ID: 31796535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micro RNAs as potential biomarkers in tuberculosis: A systematic review.
    Pattnaik B; Patnaik N; Mittal S; Mohan A; Agrawal A; Guleria R; Madan K
    Noncoding RNA Res; 2022 Mar; 7(1):16-26. PubMed ID: 35128217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing the mTOR Pathway for Tuberculosis Treatment.
    Singh P; Subbian S
    Front Microbiol; 2018; 9():70. PubMed ID: 29441052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-889 Inhibits Autophagy To Maintain Mycobacterial Survival in Patients with Latent Tuberculosis Infection by Targeting TWEAK.
    Chen DY; Chen YM; Lin CF; Lo CM; Liu HJ; Liao TL
    mBio; 2020 Jan; 11(1):. PubMed ID: 31992621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-Mediated Immune Responses to
    Coppola M; Villar-Hernández R; van Meijgaarden KE; Latorre I; Muriel Moreno B; Garcia-Garcia E; Franken KLMC; Prat C; Stojanovic Z; De Souza Galvão ML; Millet JP; Sabriá J; Sánchez-Montalva A; Noguera-Julian A; Geluk A; Domínguez J; Ottenhoff THM
    Front Immunol; 2020; 11():103. PubMed ID: 32117257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small RNA Profiles of Serum Exosomes Derived From Individuals With Latent and Active Tuberculosis.
    Lyu L; Zhang X; Li C; Yang T; Wang J; Pan L; Jia H; Li Z; Sun Q; Yue L; Chen F; Zhang Z
    Front Microbiol; 2019; 10():1174. PubMed ID: 31191492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human genetic background in susceptibility to tuberculosis.
    Ghanavi J; Farnia P; Farnia P; Velayati AA
    Int J Mycobacteriol; 2020; 9(3):239-247. PubMed ID: 32862155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between active pulmonary tuberculosis and miRNA-146a: A preliminary study from Serbia.
    Buha I; Škodrić-Trifunović V; Anđelković M; Pavlović S; Vreća M; Stjepanović M; Milin-Lazović J; Simić M; Antonijević G; Spasovski V
    J Infect Dev Ctries; 2022 Aug; 16(8):1317-1322. PubMed ID: 36099375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.
    Prezzemolo T; Guggino G; La Manna MP; Di Liberto D; Dieli F; Caccamo N
    Front Immunol; 2014; 5():180. PubMed ID: 24795723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of non-coding RNAs in tuberculosis and their potential for clinical applications.
    Jumat MI; Sarmiento ME; Acosta A; Chin KL
    J Appl Microbiol; 2023 Jun; 134(6):. PubMed ID: 37197901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.